BR112018002941A2 - métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatina - Google Patents
métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatinaInfo
- Publication number
- BR112018002941A2 BR112018002941A2 BR112018002941A BR112018002941A BR112018002941A2 BR 112018002941 A2 BR112018002941 A2 BR 112018002941A2 BR 112018002941 A BR112018002941 A BR 112018002941A BR 112018002941 A BR112018002941 A BR 112018002941A BR 112018002941 A2 BR112018002941 A2 BR 112018002941A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxaliplatin
- liposomal irinotecan
- pancreatic cancer
- methods
- metastatic pancreatic
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 3
- 229960004768 irinotecan Drugs 0.000 title abstract 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 title abstract 3
- 229960001756 oxaliplatin Drugs 0.000 title abstract 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 2
- 230000001394 metastastic effect Effects 0.000 title abstract 2
- 206010061289 metastatic neoplasm Diseases 0.000 title abstract 2
- 201000002528 pancreatic cancer Diseases 0.000 title abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 2
- 229960002949 fluorouracil Drugs 0.000 abstract 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 abstract 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 abstract 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 1
- 235000008191 folinic acid Nutrition 0.000 abstract 1
- 239000011672 folinic acid Substances 0.000 abstract 1
- 229960001691 leucovorin Drugs 0.000 abstract 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562208209P | 2015-08-21 | 2015-08-21 | |
US62/208,209 | 2015-08-21 | ||
US201562216736P | 2015-09-10 | 2015-09-10 | |
US62/216,736 | 2015-09-10 | ||
US201562273244P | 2015-12-30 | 2015-12-30 | |
US201662281473P | 2016-01-21 | 2016-01-21 | |
US62/281,473 | 2016-01-21 | ||
US201662302341P | 2016-03-02 | 2016-03-02 | |
US62/302,341 | 2016-03-02 | ||
US201662323245P | 2016-04-15 | 2016-04-15 | |
US62/323,245 | 2016-04-15 | ||
US201662343313P | 2016-05-31 | 2016-05-31 | |
PCT/US2016/047727 WO2017034957A1 (en) | 2015-08-21 | 2016-08-19 | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018002941A2 true BR112018002941A2 (pt) | 2018-11-27 |
BR112018002941B1 BR112018002941B1 (pt) | 2023-12-05 |
Family
ID=58100730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018002941-6A BR112018002941B1 (pt) | 2015-08-21 | 2016-08-19 | Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas |
Country Status (18)
Country | Link |
---|---|
US (3) | US20170049775A1 (pt) |
EP (2) | EP3337478B1 (pt) |
JP (3) | JP2018528185A (pt) |
KR (1) | KR20180039087A (pt) |
CN (1) | CN108495629A (pt) |
AU (1) | AU2016310476B8 (pt) |
BR (1) | BR112018002941B1 (pt) |
CA (1) | CA2993451A1 (pt) |
ES (1) | ES2826826T3 (pt) |
HK (2) | HK1257220A1 (pt) |
IL (1) | IL257149A (pt) |
MX (1) | MX2018001802A (pt) |
PT (1) | PT3337478T (pt) |
RU (1) | RU2747124C2 (pt) |
SG (1) | SG10201913077QA (pt) |
SI (1) | SI3337478T1 (pt) |
TW (4) | TW202126293A (pt) |
WO (1) | WO2017034957A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
JP7113619B2 (ja) * | 2014-12-09 | 2022-08-05 | イプセン バイオファーム リミティド | リポソーマルイリノテカンによる乳がんの治療 |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
WO2017031442A1 (en) | 2015-08-20 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
CA2993451A1 (en) | 2015-08-21 | 2017-03-02 | Ipsen Biopharm Ltd. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
BR122021024957B1 (pt) | 2015-10-16 | 2023-12-12 | Ipsen Biopharm Ltd | Processos de produção de uma composição de irinotecano lipossômico estabilizado em armazenamento |
US11071726B2 (en) * | 2016-11-02 | 2021-07-27 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) |
BR112021007318A2 (pt) * | 2018-10-17 | 2021-08-31 | Biolinerx Ltd. | Tratamento de adenocarcinoma pancreático metastático |
US20220072087A1 (en) * | 2019-01-17 | 2022-03-10 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
CN113613628A (zh) | 2019-02-22 | 2021-11-05 | 诺沃库勒有限责任公司 | 使用与XELOX或FOLFOX组合的TTFields治疗胃癌 |
CA3157379A1 (en) * | 2019-10-10 | 2021-04-15 | The University Of North Carolina At Chapel Hill | Delivery system complexes comprising a precipitate of an active agent and methods of use |
WO2022266354A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napoli |
WO2022266357A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napox |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
EP0949906A4 (en) | 1996-10-22 | 2004-11-24 | Hermes Biosciences Inc | LIPOSOMES LOADED WITH ACTIVE SUBSTANCE AND THEIR PRODUCTION METHOD |
US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
BR9914601A (pt) | 1998-09-16 | 2001-10-23 | Alza Corp | Inibidor de topoisomerase capturado por lipossoma |
US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
AU4564200A (en) | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
US7025988B2 (en) | 2000-02-04 | 2006-04-11 | Lipoxen Technologies Limited | Liposomes |
US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
NZ522766A (en) | 2000-05-15 | 2005-09-30 | Celgene Corp | Compositions and methods for the treatment of colorectal cancer with irinotecan and thalidomide to reduce side effects |
JP2004501955A (ja) | 2000-06-30 | 2004-01-22 | アイネックス ファーマシューティカルズ コーポレイション | リポソーム抗新生物薬剤およびその使用 |
TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
HUP0303616A3 (en) | 2001-03-26 | 2006-07-28 | Alza Corp Mountain View | Liposome composition for improved intracellular delivery of a therapeutic agent |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
EP1408974A2 (en) | 2001-07-23 | 2004-04-21 | Epidauros Biotechnologie AG | Methods for treatment of cancer using irinotecan based on ugt1a1 |
US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
EP3100719A3 (en) | 2002-05-15 | 2017-02-22 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
ATE458751T1 (de) | 2002-05-31 | 2010-03-15 | Transmolecular Inc | Kombinationschemotherapie mit chlorotoxin |
AU2003296897A1 (en) | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
ME00425B (me) | 2003-05-30 | 2011-10-10 | Genentech Inc | Liječenje sa anti-vegf antitijelima |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
KR101223366B1 (ko) | 2004-05-03 | 2013-01-16 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
UA85099C2 (en) | 2004-06-01 | 2008-12-25 | Кабусики Кайся Якулт Хонса | Liposomal irinotecan preparation |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
US20100189771A1 (en) | 2005-10-25 | 2010-07-29 | Lawrence Mayer | Fixed ratio drug combination treatments for solid tumors |
US20090148506A1 (en) | 2005-12-22 | 2009-06-11 | Awa Dicko | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
US20070265324A1 (en) | 2006-01-17 | 2007-11-15 | Wolfgang Wernet | Combination Therapy with Parp Inhibitors |
CA2647297A1 (en) | 2006-03-16 | 2007-09-27 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
CN101878229A (zh) | 2007-09-28 | 2010-11-03 | 巴塞尔大学医院 | 用于治疗癌症的免疫脂质体 |
CA2705417A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
CN101888777A (zh) | 2007-12-07 | 2010-11-17 | 彼帕科学公司 | 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症 |
JP2011515478A (ja) | 2008-03-25 | 2011-05-19 | シェーリング コーポレイション | 結腸直腸がんを処置または予防するための方法 |
US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
CA2721093A1 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
NZ596365A (en) * | 2009-05-01 | 2013-11-29 | Oncozyme Pharma Inc | Pentamidine combinations for treating cancer |
BR112012012151B8 (pt) | 2009-12-03 | 2021-05-25 | Jiangsu Hengrui Medicine Co | lipossoma de irinotecano ou cloridrato de irinotecano, método de preparação do mesmo, bem como injeção de lipossoma e processo de preparação da mesma |
WO2011153010A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Biosciences, Llc | Methods of treatment of pancreatic cancer |
EP2595618A1 (en) | 2010-07-19 | 2013-05-29 | BiPar Sciences, Inc. | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
CN103168104B (zh) | 2010-07-22 | 2016-09-28 | 加利福尼亚大学董事会 | 抗肿瘤抗原抗体及其使用方法 |
WO2012031293A1 (en) | 2010-09-03 | 2012-03-08 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of cancer |
CN103327983A (zh) | 2010-12-06 | 2013-09-25 | 梅里麦克制药股份有限公司 | 在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药 |
JP5947807B2 (ja) | 2010-12-14 | 2016-07-06 | テクニカル ユニバーシティ オブ デンマークTechnical University Of Denmark | ナノ粒子組成物への放射性核種の封入 |
CA2827118A1 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
CA2833643A1 (en) | 2011-04-19 | 2012-10-26 | Merrimack Pharmaceuticals, Inc. | Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
AU2013201584A1 (en) | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
US9511155B2 (en) | 2012-04-17 | 2016-12-06 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
WO2014113167A1 (en) | 2012-12-14 | 2014-07-24 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
AU2014245147B2 (en) | 2013-03-27 | 2017-08-31 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent including low-dose irinotecan hydrochloride hydrate |
US10111871B2 (en) | 2013-08-27 | 2018-10-30 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
US20160303264A1 (en) | 2013-10-23 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for non-invasive imaging and drug delivery |
JP7113619B2 (ja) | 2014-12-09 | 2022-08-05 | イプセン バイオファーム リミティド | リポソーマルイリノテカンによる乳がんの治療 |
TW201701880A (zh) | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
WO2017031442A1 (en) | 2015-08-20 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
CA2993451A1 (en) | 2015-08-21 | 2017-03-02 | Ipsen Biopharm Ltd. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
BR122021024957B1 (pt) | 2015-10-16 | 2023-12-12 | Ipsen Biopharm Ltd | Processos de produção de uma composição de irinotecano lipossômico estabilizado em armazenamento |
US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
SG11201809788VA (en) | 2016-05-18 | 2018-12-28 | Ipsen Biopharm Ltd | Nanoliposomal irinotecan for use in treating small cell lung cancer |
CN106420789A (zh) * | 2016-10-08 | 2017-02-22 | 中国人民解放军总医院 | 复发耐药消化道肿瘤地西他滨综合治疗方案 |
US11071726B2 (en) | 2016-11-02 | 2021-07-27 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) |
-
2016
- 2016-08-19 CA CA2993451A patent/CA2993451A1/en active Pending
- 2016-08-19 TW TW109134982A patent/TW202126293A/zh unknown
- 2016-08-19 WO PCT/US2016/047727 patent/WO2017034957A1/en active Application Filing
- 2016-08-19 ES ES16758337T patent/ES2826826T3/es active Active
- 2016-08-19 MX MX2018001802A patent/MX2018001802A/es unknown
- 2016-08-19 EP EP16758337.6A patent/EP3337478B1/en active Active
- 2016-08-19 CN CN201680046873.3A patent/CN108495629A/zh active Pending
- 2016-08-19 PT PT167583376T patent/PT3337478T/pt unknown
- 2016-08-19 JP JP2018506600A patent/JP2018528185A/ja not_active Withdrawn
- 2016-08-19 EP EP20190127.9A patent/EP3791876A1/en active Pending
- 2016-08-19 AU AU2016310476A patent/AU2016310476B8/en active Active
- 2016-08-19 RU RU2018105666A patent/RU2747124C2/ru active
- 2016-08-19 US US15/241,106 patent/US20170049775A1/en not_active Abandoned
- 2016-08-19 SG SG10201913077QA patent/SG10201913077QA/en unknown
- 2016-08-19 TW TW105126833A patent/TWI778942B/zh active
- 2016-08-19 KR KR1020187005220A patent/KR20180039087A/ko not_active Application Discontinuation
- 2016-08-19 TW TW112110238A patent/TW202400181A/zh unknown
- 2016-08-19 BR BR112018002941-6A patent/BR112018002941B1/pt active IP Right Grant
- 2016-08-19 SI SI201630927T patent/SI3337478T1/sl unknown
- 2016-08-19 TW TW111103869A patent/TW202243677A/zh unknown
-
2017
- 2017-11-10 US US15/809,815 patent/US11344552B2/en active Active
-
2018
- 2018-01-25 IL IL257149A patent/IL257149A/en unknown
- 2018-12-18 HK HK18116225.3A patent/HK1257220A1/zh unknown
- 2018-12-19 HK HK18116310.9A patent/HK1257250A1/zh unknown
-
2021
- 2021-10-28 JP JP2021176412A patent/JP7463329B2/ja active Active
-
2022
- 2022-04-01 US US17/711,500 patent/US20230062425A1/en active Pending
-
2024
- 2024-02-16 JP JP2024022222A patent/JP2024045587A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018002941A2 (pt) | métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatina | |
BR112019007844A2 (pt) | tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina) | |
PH12017502154A1 (en) | Methods for conditioning patients for t cell therapy | |
AU2018201942B2 (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
WO2016025635A3 (en) | Combination therapy for treating cancer | |
MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
MX2016015363A (es) | Terapias de combinacion para el tratamiento de cancer. | |
BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
WO2015184145A8 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
MX2018013663A (es) | Metodos para tratar trastornos de sueño de ritmo circadiano. | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
MA40364A (fr) | Polythérapie pour le traitement du cancer | |
PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
WO2014106459A3 (en) | Method for treating tumor by using recombinant interferon with changed spatial configuration | |
BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
PH12018500450A1 (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
MX2019003314A (es) | Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3). | |
MX2018004112A (es) | Terapia de combinacion racional para el tratamiento de cancer. | |
EA201891005A1 (ru) | Комбинированная терапия рака |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/08/2016, OBSERVADAS AS CONDICOES LEGAIS |